953071-73-3

Basic information

• Product Name: tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate;Bilastine Impurity 1;tert-Butyl 4-(1H-benzimidazol-2-yl)piperidine-1-carboxylate;2-Methyl-2-propanyl 4-(1H-benzimidazol-2-yl)-1-piperidinecarboxylate
• CAS NO: 953071-73-3
• Molecular Formula: C₁₇H₂₃N₃O₂
• Molecular Weight: 301.38342
• Product Categories: API;Piperidine, heterocyclic
• Mol File: 953071-73-3.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 497.1±38.0 °C(Predicted)
• Appearance: /
• Density: 1.184±0.06 g/cm3(Predicted)
• PKA: 11.83±0.10(Predicted)
• CAS DataBase Reference: tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate(953071-73-3)
• EPA Substance Registry System: tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate(953071-73-3)

Safety Data

• Hazardous Substances Data: 953071-73-3(Hazardous Substances Data)

Usage

Description

Tert-butyl 4-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate is a synthetic chemical compound characterized by a molecular structure that features a piperidine ring fused to a benzo[d]imidazole group and a tert-butyl ester. tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate is recognized for its potential in medicinal chemistry, serving as a versatile building block for the creation of therapeutic agents. Its unique structural attributes and functional groups render it a promising precursor in the development of novel drugs aimed at addressing a spectrum of medical conditions.

Uses

Used in Medicinal Chemistry:
Tert-butyl 4-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate is utilized as a key building block for the synthesis of potential therapeutic agents. Its incorporation into various chemical frameworks allows for the exploration of new drug candidates with improved pharmacological profiles.
Used in Research and Development:
In the realm of pharmaceutical research, tert-butyl 4-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate serves as an invaluable research tool. It is employed to investigate the biological activity and pharmacological properties of its derivatives, providing insights into their potential applications in treating specific medical conditions.
Used in Drug Development:
tert-butyl 4-(1H-benzo[d]iMidazol-2-yl)piperidine-1-carboxylate is also used in the development of new drugs targeting a range of medical conditions. Its unique structure and functional groups enable the design of molecules with enhanced efficacy, selectivity, and safety profiles, contributing to the advancement of novel therapeutic options for patients.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 38385-95-4 2-(4-piperidinyl)-1H-benzimidazole 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 95-54-5 1,2-diamino-benzene 
• 498-94-2 isonipecotic acid 
• 88-74-4 2-nitro-aniline 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 

Downstream Products

• 38385-95-4 2-(4-piperidinyl)-1H-benzimidazole 
• 1181267-38-8 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidine]ethyl]-α,α-dimethylphenylacetic acid methyl ester 
• 202189-78-4 Bilastine 
• 110963-63-8 1-(2-ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole 
• 1181267-36-6 tert-butyl 4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate 
• 1381841-42-4 C₁₉H₂₀ClN₃ 

Relevant articles and documents

TITLE: PROCESS FOR THE PREPARATION OF BILASTINE

The present invention relates to a process for the preparation of bilastine, a compound of formula I. The present invention relates to p-xylene solvate of bilastine and process for its preparation. The present invention relates to a process for the prepar

SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

Bilastine preparation method

The invention discloses a Bilastine preparation method. The Bilastine preparation method includes that 2-nitroaniline which is low in price and easy to obtain is taken as a raw material which is subjected to reduction-n-cyclohexylmaleimide reaction, alkyl